CLK1/2-IN-3

TargetMol
Product Code: TAR-T23897
Supplier: TargetMol
CodeSizePrice
TAR-T23897-5mg5mg£850.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T23897-50mg50mg£1,661.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T23897-100mg100mg£2,079.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT

Overview

Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃

Images

1 / 1

Further Information

Bioactivity:
CLK1/2-IN-3 is a selective inhibitor of CLK1 and CLK2.
CAS:
1005784-60-0
Formula:
C21H21N5O2
Molecular Weight:
375.432
Purity:
0.98
SMILES:
CC(C)(CO)c1ccc(cc1)C(=O)Nc1cn2cc(ccc2n1)-c1cn[nH]c1

References

1. Labri?re C, Lozach O, Blairvacq M, Meijer L, Guillou C. Further investigation of Paprotrain: Towards the conception of selective and multi-targeted CNS kinase inhibitors. Eur J Med Chem. 2016 Nov 29;124:920-934. doi: 10.1016/j.ejmech.2016.08.069. Epub 2016 Aug 31. PubMed PMID: 27676471. 2. Jain P, Karthikeyan C, Moorthy NS, Waiker DK, Jain AK, Trivedi P. Human CDC2-like kinase 1 (CLK1): a novel target for Alzheimer's disease. Curr Drug Targets. 2014 May;15(5):539-50. Review. PubMed PMID: 24568585. 3. Montes-Grajales D, Olivero-Verbel J. Computer-aided identification of novel protein targets of bisphenol A. Toxicol Lett. 2013 Oct 9;222(3):312-20. doi: 10.1016/j.toxlet.2013.08.010. Epub 2013 Aug 20. PubMed PMID: 23973438. 4. Wong R, Balachandran A, Mao AY, Dobson W, Gray-Owen S, Cochrane A. Differential effect of CLK SR Kinases on HIV-1 gene expression: potential novel targets for therapy. Retrovirology. 2011 Jun 17;8:47. doi: 10.1186/1742-4690-8-47. PubMed PMID: 21682887; PubMed Central PMCID: PMC3148977.